prikaz prve stranice dokumenta Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Pregledni rad
Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume
Medical Microbiology and Immunology, 208 (2019), 3-4; 415-429. https://doi.org/10.1007/s00430-019-00600-1
Krmpotić, Astrid; Podlech, Jürgen; Reddehase, Matthias J.; Britt, William J.; Jonjić, Stipan

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Krmpotić, A., Podlech, J., Reddehase, M. J., Britt, W. J. i Jonjić, S. (2019). Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume. Medical Microbiology and Immunology, 208. (3-4), 415-429. doi: 10.1007/s00430-019-00600-1

Krmpotić, Astrid, et al. "Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume." Medical Microbiology and Immunology, vol. 208, br. 3-4, 2019, str. 415-429. https://doi.org/10.1007/s00430-019-00600-1

Krmpotić, Astrid, Jürgen Podlech, Matthias J. Reddehase, William J. Britt i Stipan Jonjić. "Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume." Medical Microbiology and Immunology 208, br. 3-4 (2019): 415-429. https://doi.org/10.1007/s00430-019-00600-1

Krmpotić, A., et al. (2019) 'Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume', Medical Microbiology and Immunology, 208(3-4), str. 415-429. doi: 10.1007/s00430-019-00600-1

Krmpotić A, Podlech J, Reddehase MJ, Britt WJ, Jonjić S. Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume. Medical Microbiology and Immunology [Internet]. 2019. [pristupljeno 15.05.2024.];208(3-4):415-429. doi: 10.1007/s00430-019-00600-1

A. Krmpotić, J. Podlech, M. J. Reddehase, W. J. Britt i S. Jonjić, "Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume", Medical Microbiology and Immunology, vol. 208, br. 3-4, str. 415-429, 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:665142. [Citirano: 15.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:665142
Podaci o radu
Naslov (engleski)Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume
AutorAstrid Krmpotić
AutorJürgen Podlech
AutorMatthias J. Reddehase
AutorWilliam J. Britt
AutorStipan Jonjić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za histologiju i embriologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Cytomegaloviruses (CMVs) are highly prevalent herpesviruses, characterized by strict species specificity and the ability to establish non-productive latent infection from which reactivation can occur. Reactivation of latent human CMV (HCMV) represents one of the most important clinical challenges in transplant recipients secondary to the strong immunosuppression. In addition, HCMV is the major viral cause of congenital infection with severe sequelae including brain damage. The accumulated evidence clearly shows that cellular immunity plays a major role in the control of primary CMV infection as well as establishment and maintenance of latency. However, the efficiency of antiviral antibodies in virus control, particularly in prevention of congenital infection and virus reactivation from latency in immunosuppressed hosts, is much less understood. Because of a strict species specificity of HCMV, the role of antibodies in controlling CMV disease has been addressed using murine CMV (MCMV) as a model. Here, we review and discuss the role played by the antiviral antibody response during CMV infections with emphasis on latency and reactivation not only in the MCMV model, but also in relevant clinical settings. We provide evidence to conclude that antiviral antibodies do not prevent the initiating molecular event of virus reactivation from latency but operate by preventing intra-organ spread and inter-organ dissemination of recurrent virus.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMedical Microbiology and Immunology
Brojčani podacivol. 208, br. 3-4, str. 415-429
p-ISSN0300-8584
DOIhttps://doi.org/10.1007/s00430-019-00600-1
URN:NBNurn:nbn:hr:184:665142
Datum objave publikacije2019
ProjektŠifra: KK.011.1.01.0006
Naziv (hrvatski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: ERDF
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
URL dokumentahttp://bib.irb.hr/1049584
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-03-08 11:37:21